Claus-Peter Schneider

Claus-Peter Schneider

UNVERIFIED PROFILE

Are you Claus-Peter Schneider?   Register this Author

Register author
Claus-Peter Schneider

Claus-Peter Schneider

Publications by authors named "Claus-Peter Schneider"

Are you Claus-Peter Schneider?   Register this Author

14Publications

370Reads

47Profile Views

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Oct 30;35(30):3449-3457. Epub 2017 Aug 30.

Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University, Seoul; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju-si, Republic of Korea; Claus-Peter Schneider, Zentralklinik Bad Berka, Bad Berka; Joachim Von Pawel, Asklepius Fachkliniken, Gauting; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pablo Fernando Gonzalez Mella, Centro de Investigaciones Clinicas, Universidad de Valparaíso and Fundación Arturo López Pérez, Santiago, Chile; Fabrice Barlesi, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Baohui Han, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai; Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China; Doina Elena Ganea, Spitalul Judetean De Urgenta Suceava, Sfântul loan cel Nou, Suceava, Romania; Vladimir Vladimirov, State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk; Natalia Fadeeva, Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Tomohide Tamura, St Luke's International Hospital, Tokyo, Japan; Pieter E. Postmus, University of Liverpool, Liverpool, United Kingdom; Kenneth O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia; and Justin Kopit, Mingshun Li, and Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.7629
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.7629DOI Listing
October 2017

Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.

Oncologist 2014 Oct 17;19(10):1100-9. Epub 2014 Sep 17.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Division of Thoracic Oncology, Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany, Department of Medical Oncology, Klinik Löwenstein, Löwenstein, Germany; Department of Respiratory Medicine, Evangelische· Lungenklinik, Berlin, Germany; Department of Pneumology, Evangelisches Diakonissenkrankenhaus, Leipzig, Germany; Translational Lung Research Center Heidelberg, Heidelberg, Germany; Department of Pneumology and Thoracic Oncology, Klinik Schillerhoehe, Gerlingen, Germany; Department of Hematology and Medical Oncology, Zentralklinik, Bad Berka, Germany; Haemato-Oncology Hamburg, Hamburg, Germany; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200993PMC
October 2014

Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.

J Thorac Oncol 2014 Aug;9(8):1154-61

*Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy; †Thoracic Surgery Department, Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine; ‡Sumy Regional Oncology Centre, Sumy State University, Sumy, Ukraine; §Centrul de Oncologie Medicala, Iasi, Romania; ‖Central Hospital Bad Berka, Bad Berka, Germany; ¶Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; #Department of Biostatistics & Epidemiology, Amgen Inc., South San Francisco; **Department of Oncology, Amgen Inc., Thousand Oaks, CA; and ††Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000227DOI Listing
August 2014

Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology.

Ann Nucl Med 2012 May 25;26(4):365-9. Epub 2012 Feb 25.

THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, 99437, Bad Berka, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-012-0578-3DOI Listing
May 2012

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.

Clin Chem Lab Med 2005 ;43(6):617-27

Abteilung für Experimentalle Hämatologie und Onkologie der Klinik für Innere Medizin II, Friedrich Schiller Universität Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2005.107DOI Listing
October 2005

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.

Clin Lung Cancer 2003 Mar;4(5):294-7

Second Medical Department, City hospital Martha-Maria Halle-Doelau, Halle, Germany.

View Article

Download full-text PDF

Source
March 2003

[Current trends in pneumology 2002 -- Part 1].

Med Klin (Munich) 2003 Jan;98(1):30-56

Pneumologie & Allerologie/Immunologie, Medizinische Klinik IV, Friedrich-Schillier-Universität, Jena.

View Article

Download full-text PDF

Source
January 2003